Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

Eli Lilly And Co (NASDAQ: LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector.

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...